Alopexx Announces Investment from Biotech Consortia, Inc. - BioSpace

Alopexx, Inc. receives investment from Biotech Consortia, Inc. to advance AV0328, a broad-spectrum anti-microbial vaccine targeting PNAG, with potential to treat bacterial, fungal, and parasitic infections. AV0328 completed Phase I trials, showing tolerance and antibody induction against PNAG-expressing pathogens, with an affordable cost of $1 per dose.